Search results for "Adverse effect"

showing 10 items of 1065 documents

MMR and MMRV vaccines.

2018

Measles, mumps, rubella and varicella are viral infections which can implicate seriously long-term sequelae of infected individuals or even the unborn child. Vaccines against the individual diseases have long been available. Global measles vaccination is estimated to have prevented more than 20million deaths during 2000-2015. During the same time period, measles incidence decreased from 146 to 36 cases per million populations. Today vaccinations against measles, mumps, rubella and varicella are now carried out mainly with combination vaccines. These are today known as immunogenic and safe. MMRV had similar immunogenicity and overall safety profiles to MMR administered with or without varice…

Varicella vaccineRubellaMeasles03 medical and health sciences0302 clinical medicineChickenpox030225 pediatricsmedicineHumans030212 general & internal medicineAdverse effectMumpsRubellaVaccinesGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityIncidence (epidemiology)VaccinationPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicinebusinessMeaslesVaccine
researchProduct

Correction of the unfavourable effects of vasopressin by nitroglycerin infusion

1982

Nitroglycerin was administered with vasopressin to prevent adverse effects. Vasopressin 0.25U . 70 kg-1 min-1 was infused intravenously in four dogs for 40 minutes, when a venous infusion of nitroglycerin 1.2 micrograms . kg-1 . min-1 was added for 20 minutes. Nitroglycerin 1.2 micrograms . kg-1 . min-1 alone was infused intravenously in another four dogs for 40 minutes. The venous blood pressures (mesenteric and central) and arterial pressures (mesenteric and femoral), the electrocardiogram and arterio-venous difference were recorded. Nitroglycerin was shown to annul the unfavourable effects of vasopressin without altering its efficacy upon portal pressure.

Vasopressinmedicine.medical_specialtyTime FactorsCentral Venous PressureVasopressinsPortal venous pressureBlood PressureNitroglycerinDogsOxygen ConsumptionHeart RateAnesthesiologyAnimalsMedicineInfusions Parenteralcardiovascular diseasesAdverse effectNitroglycerinbusiness.industryGeneral MedicineVenous Blood PressuresAnesthesiology and Pain MedicineAnesthesiacardiovascular systembusinesscirculatory and respiratory physiologymedicine.drugCanadian Anaesthetists’ Society Journal
researchProduct

Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts’ study

2021

ABSTRACTObjectiveTo assess safety and efficacy of nusinersen in adult 5q spinal muscular atrophy (SMA) patients.MethodsPatients older than 15 years and followed at least for 6 months with one motor scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Clinical and patients’ global impression of change (CGI-C and PGI-C) were recorded in treated patients at the last visit. Functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) and the percent-predicted forced vital capacity were collected when available.ResultsSeventy-nine SMA patients (39 treated with n…

Vital capacitymedicine.medical_specialtybusiness.industrySpinal muscular atrophySMA*medicine.diseasemedicine.anatomical_structureRating scaleInternal medicinemedicineUpper limbNusinersenAmyotrophic lateral sclerosisbusinessAdverse effect
researchProduct

Safety of micafungin in prospective and retrospective clinical trials

2012

Summary Managing fungal diseases remains a major challenge for clinicians despite the improved armamentarium of antifungal agents. This review identified 19 publications reporting safety data on micafungin. Two of these publications were spin off publications, the remaining 17 (15 prospective, two retrospective) were included in the main assessment. Major adverse events reported which occurred in more than 2% in the study populations were infusion-related, gastro-intestinal and hepatic (LFT parameters elevations). Micafungin demonstrated significantly less renal events compared with liposomal amphotericin B and less hepatic events compared with voriconazole. Compared with fluconazole no sig…

VoriconazolebiologyEchinocandinbusiness.industryMicafunginDermatologyGeneral Medicinebacterial infections and mycosesbiology.organism_classificationInfectious DiseasesImmunologymedicineChillsmedicine.symptombusinessAdverse effectCandida albicansEchinocandinsFluconazolemedicine.drugMycoses
researchProduct

Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial

2010

Abstract Abstract 2309 Objectives. Treatment of invasive aspergillosis (IA) fails in up to 50% of all cases and the mortality rate is at least 30%. Antifungal combination treatment has not been proven to be beneficial and dose escalation with liposomal amphotericin B did not improve outcome. New approaches are needed for patients with severe immunosuppression. Methods. Escalating high dosages of caspofungin were investigated in IA defined according to modified EORTC/MSG criteria. The tested cohort of patients received 70mg, 100mg, 150mg or 200mg QD, 8 patients each were to receive caspofungin first-line treatment for proven/probable IA for up to 28 days. Dose limiting toxicity was defined a…

Voriconazolemedicine.medical_specialtyDosebusiness.industryMortality rateImmunologyCell BiologyHematologyAspergillosismedicine.diseaseBiochemistrySurgerychemistry.chemical_compoundchemistryInternal medicineToxicityCohortmedicineCaspofunginAdverse effectbusinessmedicine.drugBlood
researchProduct

Voriconazole and the liver.

2015

Voriconazole is an azole useful for the prophylaxis and the treatment of aspergillosis and other fungal infections in immunosuppressed subjects, as those found in aplasia after aggressive polychemotherapy treatments, after hematopoietic stem cell, liver or lung transplantation. Its administration in therapeutic doses lead to extremely varied serum levels from patient to patient and even to the same patient. The explanations are varied: nonlinear pharmacokinetics, certain patient-related factors, including genetic polymorphisms in the cytochrome P450 2C19 gene, the kidney and liver function, simultaneous administration with other drugs metabolised by the same cytochrome. It is recommended to…

Voriconazolemedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryCYP2C19Pharmacologymedicine.diseaseAspergillosisGastroenterologyEditorialCholestasisTherapeutic drug monitoringInternal medicineToxicitymedicineLiver functionbusinessAdverse effectmedicine.drugWorld journal of hepatology
researchProduct

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

1997

International audience; The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarities, but are specifically regulated at the molecular level and may be distinguished apart in their functions, although some physiological overlap between them does occur. The major goal in developing selective COX inhibitors is to improve NSAID tolerability. Classic NSAIDs preferentially inhibit COX-1 in vitro, but it appears hazardous to judge their gas…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH: Prostaglandin-Endoperoxide SynthasesAnti-Inflammatory AgentsPharmacologyNabumetoneMESH: Cyclooxygenase InhibitorsPharmacotherapymedicineMESH : Anti-Inflammatory Agents Non-SteroidalAnimalsHumansPharmacology (medical)Cyclooxygenase InhibitorsMESH: AnimalsAdverse effectMESH: HumansMESH : Prostaglandin-Endoperoxide Synthasesbusiness.industryMESH : HumansAnti-Inflammatory Agents Non-SteroidalMESH : Cyclooxygenase InhibitorsMESH: Anti-Inflammatory Agents Non-SteroidalClinical trial[SDV.AEN] Life Sciences [q-bio]/Food and NutritionMeloxicamTolerabilityProstaglandin-Endoperoxide SynthasesMESH : AnimalsCyclo-oxygenaseNon-Steroidalbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionNimesulidemedicine.drug
researchProduct

Avis de l'Anses relatif à l'actualisation de la méthode d'imputabilité des signalements d'effets indésirables de nutrivigilance

2019

A l’instar des autres systèmes de vigilance français et compte tenu de l’importance des conséquences en matière de santé et des décisions industrielles qui en découlent, l’analyse de la relation de causalité entre un produit visé par le dispositif national de nutrivigilance et l’effetindésirable déclaré doit être réalisée avec une méthode d’analyse appropriée et objective. Cette méthode dite « méthode d’imputabilité de nutrivigilance » estime le degré de causalité, d’un ou de plusieurs produits dans la survenue de l’effet indésirable déclaré, de manière standardisée, permettant d’éliminer les divergences d’opinion pouvant exister entre plusieurs observateurs. De telles méthodes sont couramm…

[SDV.AEN] Life Sciences [q-bio]/Food and NutritionComplément circonstancielImputabilitéFood supplementNutrivigilanceCausality assessmentEffet indésirableNutritional assessmentAdverse effectNutrition assessmentMESH: Nutrition Assessment[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

2021

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…

adverse events; dolutegravir; durability; HIV; safety; toxicity; virolgical failure; Cohort Studies; Female; Heterocyclic Compounds 3-Ring; Humans; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Anti-HIV Agents; HIV InfectionssafetyPediatricsmedicine.medical_specialtySettore MED/17 - Malattie InfettivePyridonesAnti-HIV AgentsOxazineHuman immunodeficiency virus (HIV)adverse eventHIV Infectionsvirolgical failurePyridonemedicine.disease_cause3-RingHIV Infections.PiperazinesCohort Studieschemistry.chemical_compoundHeterocyclic CompoundsHIV; adverse events; dolutegravir; durability; safety; toxicity; virolgical failureOxazinesAntiretroviral treatmentMedicineHumansProspective StudiesAdverse effectPiperazinebusiness.industryPublic Health Environmental and Occupational HealthHIVtoxicityAnti-HIV AgentMiddle Agedadverse eventsDiscontinuationdolutegravirvirolgical failure.Prospective StudieInfectious DiseaseschemistryDolutegravirdurabilityObservational studyFemaleCohort StudiebusinessHeterocyclic Compounds 3-RingHuman
researchProduct

Oral Allergy Syndrome (OAS). General and stomatological aspects

2008

Oral Allergy Syndrome (OAS) is a special contact allergy conditioned by specific amino acids in food allergens, usually fruits, as well as some proteins from different pollens. It is usually manifested in the mouth, however relatively little is known about the syndrome in Odontology. OAS is a fairly common adverse reaction that occurs after ingesting certain foods, such as peaches or apples, produced in atopic individuals who usually suffer from rhinitis, bronchial asthma or both. This syndrome mainly affects the oral cavity and oropharynx, provoking minor local alterations, although there may be serious systematic reactions, making it important to distinguish it from other oral processes w…

business.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOral cavityOtorhinolaryngologyOral allergy syndromeContact allergyImmunologyUNESCO::CIENCIAS MÉDICASmedicineHypersensitivityHumansSurgeryFood allergensbusinessAdverse effectMouth DiseasesGeneral DentistryAnaphylaxisFood HypersensitivityAsthma
researchProduct